This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Lilly Innovation Partnering
Lilly European Innovation Partnering
July 12–16, 2021Delivered Digitally
Lilly European Innovation Partnering
July 12–16, 2021,
Delivered Digitally



Life sciences therapeutics companies are exclusively invited to meet one-on-one with Eli Lilly and Company to explore how we can accelerate science together, by forging partnerships to rapidly deliver innovative medicines for the benefit of patients.

A message from

Ken Custer
VP of Business Development and Lilly New Ventures


Collaboration. Acceleration. Investment. We specialize in helping early innovation grow into impactful medicines.

  • Lilly is dedicated to searching the globe for exciting scientific breakthroughs that have the potential to positively impact our future and ensure that we all live healthier, longer, fuller lives.
  • We always start with the science. We are committed to creatively, flexibly, and efficiently building partnerships to progress the science we believe in.
  • Lilly offers deep scientific and business expertise, state-of-the-art facilities, cutting edge capabilities and decades of experience developing ideas into tangible treatments.
  • By connecting this with entrepreneurs who create and build transformative companies and treatments, we empower innovators to deliver medicines to patients in need.

And we have the track record to show it. Here’s some of the things we’ve been up to:

AveXis name recognition and Zolgensma legacy hook Lilly in Jaguar's $139M series B 
April 13, 2021

Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
March 17, 2021

University of Glasgow Announces Research Collaboration with Lilly to Discover Potential New Drug Targets
February 15, 2021

Lilly Announces Agreement to Acquire Prevail Therapeutics
December 15, 2020

Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement
November 20, 2020

Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement with Lilly
June 09, 2020

Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines
March 31, 2020

Helmholtz Zentrum München allies with Eli Lilly and Company to discover new targets for pancreatic beta cell regeneration in the treatment of diabetes
October 25, 2019

Lilly and Dicerna Announce RNAi Licensing and Research Collaboration
October 29, 2018

Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes
April 04, 2018

David A. Ricks

Chairman and CEO

Eli Lilly and Company

We’re trying to change the frontiers of what’s possible in medicine. Our vision is to change patients’ expectations – to provide a new sense of hope for people suffering from some of the world’s most debilitating diseases.